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Overexpression of the unconventional motor protein myosin VI (MYOVI) has been seen in aggressive 
cancer phenotypes. Its ability to interact with numerous intracellular pathways influences downstream 
targets and promotes cell growth. Recently MYOVI has been found to positively impact the ER pathway 
directly through the estrogen receptor. Activation of this receptor results in downstream sign ling via 
estrogen responsive elements (EREs) to regulate transcription of a vast plethora of genes including P53. 
Furthermore interactions with Dab2, which binds to the WWY motif located in MYOVI’s cargo binding 
domain, hinder MYOVI’s functionality in transcription factories within the nucleus, hence negatively 
impacting ER-driven gene expression. To assess, in the context of cancer, what is regulating MYOVI 
distribution within cells we performed experiments to compare the effect of intrinsic protein interactions, 
using the ESR1-DAB2 fusion gene isolated from an endocrine therapy resistant metastatic breas  cancer 
(MBC) patient treated with tamoxifen, to extrinsic environmental changes, in this case hypoxia. While the 
majority of breast cancers in patients are ER-positive (ER+), and hence respond to endocrine therapy, 
acquired resistance to therapy is a big problem. Determining the localization and interactions in vitro of 
ESR1-DAB2 and elucidating its association with MYOVI could highlight novel therapeutic targets in 
MBC. Hypoxia characteristics are found in many tumours and are associated with a poor prognosis. Low 
oxygen levels alter the transcriptome of cells drastically, typically favouring pathways that upregulate 
vascular endothelial growth factor (VEGF) encouraging angiogenesis to relieve the hypoxic stress. 
Microscopy revealed that the effect of ESR1-DAB2 varies between MCF7 and HeLa cell lines and 
MYOVI distribution can be compared, with the plasmid exhibiting higher toxicity in HeLa potentially 
due to the loss of ER in this cell line. While hypoxia did not result in increased expression levels of 
MYOVI, the distribution was altered depending on the duration of hypoxia. The data presented in this 
thesis is not conclusive but lays a foundation to build upon in future work and contributes to the growing 
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1.0:  Introduction: 
The actin-myosin (actomyosin) network functions within all types of cells in order to regulate a 
large plethora of cellular functions. The intracellular actin population can be categorized into 
monomeric and filamentous states, G-actin and F-actin respectively (1). Globular actin 
monomers, in the presence of ATP, are able to form a filament, where the plus end exhibits faster 
additions than the minus end. Filaments are enriched in muscle cells, due to their function as 
contractile fibers in sarcomeres alongside myosin II, but are also found in all cells owing to their 
key role as part of the cytoskeleton. In eukaryotic cells the cytoskeleton is integral for 
phagocytosis, maintainence of essential permanent structures for specific cells (such as microvilli 
in brush-border cells), ensures intra-cellular compartmental integrity, effective transportation of 
intracellular proteins and functions critically in chromosome segregation and cell division. All 
forms of myosin exhibit highly conserved actin and ATP-binding sites within the motor head 
domain. This enables their dynamic ATP-dependent interaction with actin, resulting in a range of 
cellular functions, including transportation of cargo proteins across cells to the correct cellular 
compartment (2). Myosin activation mediates endocytosis and exocytosis, as well as cell 
proliferation, adhesion and migration through the actin cytoskeleton. Tumours exhibit altered 
mechanical function of the myosins in order to favor proliferation and dissemination by 
manipulating the actomyosin network (3).  
The arrangement of the actomyosin cytoskeleton is mediated by extracellular signals transduced 
by the Rho protein family. RHO, RAC and CDC-42 are not frequently seen to be mutated in 
cancer, but misregulation of this pathway results in the observed overexpression of RAC1, RHOA 
and CDC-42 in cancer (breast cancer specifically), resulting in tumorigenesis and metastasis due 
to their influence (4,5). In light of this it is important to not only look into myosin’s expression 
and distribution but also observe how this network is altered by stressors typically observed in 
more aggressive tumours. This study focuses on observing the effect of protein and 
environmental stressors on Myosin VI within cancer cells in order to gain further understanding 





1.1: Metastatic breast cancers 
Breast cancer has been predicted to affect 1 in 8 women during their lifetime and currently 
makes up to ~30% of cancers found in women. Western Europe has the highest numbers of 
prevalence for this disease and hence progress has been made to attempt to identify risk factors 
and reduce the mortality. This has mainly been achieved through screening schemes which use 
X-rays to detect abnormalities in the breast tissue, allowing early stage breast cancers in women 
across the world to be identified, and has resulted in an impressive drop in mortality rates for this 
type of cancer (6). Genomic studies from these patients function not only as a diagnostic tool, but 
has allowed further investigation into contributing risk factors, highlighting prevalent cancer 
associated mutations, such as the inactivation of TP53 via missense mutations and more rare 
mutations like the ESR1-DAB2 fusion (92). While early detection is key for a better prognosis, it 
is also integral to consider the nature of the cancer and its characteristics in order to ascertain the 
most effective route of therapy for each individual patient (7). Endocrine therapies have 
successfully treated breast cancers that are Estrogen receptor positive (ER+), as 70% of patients 
fall into this category. Unforeseeably, 25% of these patients, with metastatic breast cancer 








Diagram 1: A cartoon displaying the structure of ERg. Domain A/B is the N terminal ligand-
independent AF-1 and is followed by the DNA binding domain (B) which also facilitates 
dimerization. These domains share 97% homology with ERく and are succeeded by a hinge 
region (D) which is not conserved between the two types of ER. Section E contains the Ligand 
binding domain and the C-terminal ligand-dependent AF-2 which is only 55% homologous to 
























Diagram 2:  Estrogen signaling in breast cancer: Membrane bound receptors EGFR and HER2 transduce 
a signaling cascade through the action of RTK’s that activate cytoplasmic proteins by phosphorylation. 
This can act in a ligand-dependent and ligand-independent manner. Estrogen facilitates the dimerisation 
of ERg on the membrane, which can then move into the nucleus where the dimer binds directly to ERE’s 
in genes involved in regulating growth, differentiation, angiogensis and apoptosis. (Diagram taken from: 
Pietras, R.J., Marquez-Garban, D.., (2007) Membrane-Associated Estrogen Receptor signaling pathways 
in human cancers, Clinical cancer research, DOI: 10.1158/1078-0432.CCR-07-1373) 
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The mechanism by which acquired resistance to selective estrogen modulators (such as 
Tamoxifen), selective ER degraders (such as Fulvestrant) and aromatase inhibitors or ovarian 
suppression techniques is unknown but recent analysis of the Estrogen receptor gene (ESR1) has 
revealed common genetic mutations across MBC patients that may facilitate resistance.   
The alterations are commonly point mutations/single nucleotide variants (SNVs) in the codons 
coding Tyr537 and Asp538 residues within the ligand binding domain (LBD) as seen in diagram 
1, altering the structure of the C terminal helix 12 in the receptor, shifting the conformation of 
the ER, hereby facilitating activation of ER-dependent transcription and proliferation as 
demonstrated in Diagram 2(8). Further studies of patients with endocrine therapy resistant MBC 
revealed the presence of an ESR1-Disabled 2 (DAB2) fusion gene in an individual treated with 
Tamoxifen (29).  
1.2: Myosin VI (MYOVI) 
This 150kDa unconventional myosin is present in both the cytoplasm and nucleus of mammalian 
cells. MYOVI performs its functions as a monomer or a dimer and has the unique ability to move 










Diagram 3: A cartoon of the motor protein Myosin VI, depicting the catalytic motor head 
domain and tail region containing the CBD. Isoform sequences are indicated in the tail 
region where these inserts result in the splice variants large insert (LI), Small insert (SI), 
LI+SI and the non-insert which contains neither amino acid sequences. 
[10] 
 
Structurally, it consists of the catalytic head domain, the converter, the medial tail, the proximal 
tail and the globular cargo binding domain (CBD) as shown below in the cartoon.  It exists as 
four isoforms, a large insert (LI), small insert (SI), large and small insert (LI+SI) and a non-insert 
(NI), which result from alternate splicing in the tail region. The ratio of isoforms is seen to vary 
between cell types where each isoform has a niche selection of binding partners in line with the 
protein’s intracellular function.  
For instance the large insert (LI) is typically 21-31 amino acids and its presence results in the 
localization of MYOVI to the apical surfaces enabling it to perform endocytic functions in 
conjunction with clathrin-pits. The non-insert (NI) has been found to be localized to the trans-
side of the Golgi, where it is active in sorting pathways (9). 
The CBD contains two motifs which mediate the interaction of MYOVI with its various binding 
partners. This allows MYOVI to perform a wide range of functions such as functioning as a 
structural scaffold in the inner ear by localization on filidopia, motor function by dimerisation 
exhibiting movement towards the negative end of actin filaments(10)in the endocytic pathway 
and functions in cell migration. The WWY motif is a highly conserved sequence facilitating the 
binding of MYOVI to DAB2, a single amino acid change in this motif results in the eradication 
of this binding site. A second RRL binding motif interacts with the glucose transporter binding 
protein and is also highly conserved (11).  
In addition to its cytoplasmic roles, nuclear MYOVI is recruited to promoter and intragenic 
regions of active genes where it is able to co-localise with RNA polymerase II (RNAPII) in 
transcription factories. Downregulation of MYOVI has been seen to result in a decrease of 
steady-state mRNA(12). Its role in epithelial cell migration, alongside the high expression levels 
seen in ovarian cancer, mean that it is currently a target for cancer therapy. Understanding it’s 
interactions within cells and how dysregulation of its downstream targets results in cancerous 
phenotypes will undoubtedly be deciphered in the next decade of research. MYOVI is a 
downstream target of the estrogen receptor (ER), where activation of ER results in the 
upregulation of MYOVI transcription which is seen in aggressive cancer types. P53 typically 
safeguards this interaction by interfering with the binding of ERg to gene promoters via a 
positive feedback loop. In ER+ cancers P53 is often mutated, losing its capability to bind ERg 
promoters, resulting in up-regulated ERg signaling and high expression of MYOVI (13). 
[11] 
 
Knockdown of MYOVI reduces the level of ER driven gene expression indicating that MYOVI 
plays a role in activating its transcriptional activity. Upregulation of MYOVI is commonly seen in 
several cancers as it is found to promote cell growth (14).
1.3: Functionality of DAB2  
The 96kDa protein DAB2 is a known binding partner of the large insert (LI) isoform of Myosin 
VI through the WWY motif located in the CBD. Notably DAB2 possesses phosphotyrosine 
binding regions which facilitate interactions with receptors and other proteins, a proline rich 
region which interacts with Ras pathways and a SYF motif within which a Myosin VI binding 
site is located (15). The interaction between MYOVI and DAB2 allows controlled targeting of 
MYOVI to lipid membranes by dimerisation. The resultant increase of helicity within the tertiary 
structure, enables MYOVI’s function as an endocytic motor, transporting and clustering 
transmembrane receptors close to a clatherin-coated pit(16).  
DAB2 has been identified as a tumour suppressor due to its regulatory capability in proliferation, 
apoptosis and autophagy. One mechanism of action involves binding growth factor receptor 
binding protein 2 (GRB2), preventing its ability to activate C-FOS and MAPK(17). In cancer 
DAB2 expression is often lost or highly limited due to hypermethylation of its promoter 
region(18). 
1.4: Functionality of ESR1 
Estrogens are involved in a whole host of biological systems within cells due to their 
functionality as nuclear recptors; these steroid hormone nuclear receptors are comprised of two 
genes, ESR1 and ESR2, which encode ERg and ERく respectively (19). We will be focusing on 
the function and structure of ERg as it is part of the fusion and interacts with MYOVI.  
The structure of ERg, as seen in Diagram 1, consists of 2 transcriptional activation domains, the 
N-terminal ligand independent AF-1 and C-terminal ligand-dependant AF-2, the ligand binding 
domain (LBD), DNA-binding and hinge domains which are located in the core of the 
protein(20). Ligand binding to ER results in the recruitment of co-regulatory proteins and the 
binding of complexes to estrogen responsive element (ERE) sites. ERE’s act in regulating the 
transcription of genes involved in numerous cellular processes. The ER responsive genes include 
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TP53 which is involved in regulating apoptosis, tumorigenesis and tumour progression(21) and 
cyclin-D1 which is involved in cell cycle progression through G1 (22). 
Activation of ER in ER positive breast cancer cells causes cytoskeletal remodeling via the 
function of moesin on actin. These rapid and dynamic alterations are triggered by ERg 
interactions with G protein Ga13 which results in recruitment of RHO-A and ROCK-2 as part of a 
cascade. Reorganisation of the cytoskeleton interferes with focal adhesion sites and hence results 
in cell migration and invasion of distant tissue sites. (23)  
Estrogen also enhances the activation of Ezrin via phosphorylation, a protein that binds actin and 
is seen to be overexpressed in breast cancer patients with a poor prognosis. This results in the 
downstream activation of PI3K. (24)  
 
ER signaling from the plasma membrane allows RAS and PI3K to be activated resulting in 
signal transduction into the nuclear membrane by JNK, ERK1/2, p38 and NFkB. These are all 
involved in regulating cellular functions such a growth and apoptosis. In breast cancers, altered 
activation of these proteins results in unmediated growth and hence the formation of a tumour. 
Mutations in the LBD of ERü result in acquired resistance to initially effective therapies. The 
mechanism of this resistance is thought to involved the action of kinases, allowing the need for 
estrogen for activation to be bypassed (25, 26).  
Tumours exhibit altered expression of ER coregulatory proteins such as metastasis associated 
protein 1 (MTA1), a transcriptional repressor of ER, which is commonly seen to be deregulated 
in breast cancers and hypoxia (27). The MTA family is comprised of MTA1, MTA2 and MTA3, 
which are 80kDa, 70kDa and 65kDa respectively polypeptides containing a BAH (bromo-
adjacent homology) domain, ELM (eukaryotic linear motif) domain and SANT (Swi3, Ada2, 
MCor and TFIIIB) domain. The BAH domain is indicated to be involved in protein-protein 
interactions whereas the SANT domain allows interaction with histones within the nucleus (28).  
 
1.5: ESR1-DAB2 gene fusion 
As mentioned previously, mutations in ESR1 are commonly found in MBC patients, such as 
TP53. However, rare mutations involving translocations of deletions in ESR1 are also seen to 
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pop up during screening, including the ESR1-DAB2 fusion gene (Fig.22). The composition of the 
fusion gene can is highlighted in supplementary Figure 1, using Uniprot.org to allow the 
homologous regions of both genes to be visualized. Mapping of the fusion revealed that the DNA 
binding domain and hinge region of ESR1 are maintained but the LBD is altered and is replaced 
by the majority of the DAB2 gene (29). Genomic instability is a hallmark of cancer and is a result 
of defects in the DNA damage repair signaling pathway followed by the bypassing of cell cycle 
check points (30). Homologous recombination to attempt to repair the DNA can result in 
translocation of another gene where this break point can occur within a gene as seen in this 
fusion (31). 
There is currently not repertoire of work on this construct and therefore it is unclear how it 
functions and why it is present specifically in MBC patients resistant to endocrine therapy. 
Elucidating the resultant protein’s activity and interactions could allow for new therapeutic 
targets to be identified. 
1.6: Hypoxia 
While studying individual proteins or mutants in disease states is informative, it is important to 
consider the tumour microenvironment to fully understand the signalling pathways in play 
resulting in the observed phenotype. Hypoxia occurs when the oxygen demand of highly 
proliferative cells is not met. This stimulates PI3K, MAPK and NFkB pathways which then 
allow the cells to survive this adverse condition by activating autophagy to decrease the rate of 
oxidative metabolism (32). It can be classified into two major types; chronic or diffusion-limited 
hypoxia and acute or perfusion-limited hypoxia (33). Chronic hypoxia induces disassembly of 
the replisome and results in permanent damage to cells whereas acute hypoxia allows for 
recovery of metabolistic functions (34). Hypoxia is associated with aggressive tumour 
phenotypes due to its ability to enhance spontaneous metastasis by manipulating expression of E-
cadherin and VEGF (35).  Double strand breaks are also observed in hypoxia and 
downregulation of DNA repair systems results in genetic instability through the build-up of 
replication errors (90). 
Hypoxic conditions specifically cause the activation of hypoxia inducible factor 1 (HIF-1). It 
functions as a hetero-dimeric protein and is involved as a transcription factor for a large number 
of target genes via its helix-loop-helix motifs that allow DNA binding. HIF’s are comprised of a 
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HIFく subunit and an oxygen- regulated g subunit (HIF-1g, HIF-2g or HIF-3g) (36).  
Downstream effects of this activation include the promotion of angiogenesis in hypoxic areas via 
binding with vascular endothelial growth factor’s (VEGF) regulatory region and regulation of 
oxygen homeostasis. This signaling is seen to be up-regulated in cancer cells and hence is a key 
current therapeutical target (37). Previous research has revealed that hypoxia increases cancer 
stem cell characteristics which are distinctive from non-hypoxic tumour cell expression. The 
PI3K/AKT pathway is a key factor in accessing this stem cell-like phenotype and this overlaps 
with the estrogen signaling pathway seen in MCF7 where NFkB and CREB are activated within 
the nucleus.  
Tumour hypoxia is typically associated with a poor patient survival. Therefore, it is specifically 
interesting to observe hypoxia induced changes in the localization and gene expression of 
proteins. In tumours, the central cells at the middle of the mass typically are necrotic due to the 
lack of oxygen (before the induction of angiogenesis) and thus, utilizing this stressor can allow 
progress to be made towards understanding how these cells survive and can be targeted within a 
tumour. (38) Hypoxic culture conditions can be achieved in a closed system incubator where all 
oxygen is removed. This can simulate the tumour microenvironment, enabling the impact of 
hypoxia on protein and processes of interest to be studied.  
1.7: Aims 
This study aimed to investigate the effect of intrinsic and extrinsic stressors on MYOVI 
expression and localization in order to determine potential interacting pathways. This is 
specifically important in respect of the cancer field as MYOVI is up-regulated in aggressive 
tumours. Therefore its interactions and signaling pathways are of interest for drug targeting and 
for use as biomarkers, potentially allowing the best method of treatment to be determined for 
each patient.  
As an intrinsic stressor, we utilized a fusion gene isolated from a therapy resistant breast cancer 
patient, the ESR1-DAB2 fusion. Dysregulation and mutations in ESR1 signaling are commonly 
seen in aggressive cancers and Dab2 has not only been characterized as a tumour suppressor, but 
it also acts as a binding partner to allow targeted binding of MYOVI LI to lipid membranes. 
Therefore, the introduction of ESR1-DAB2 into HeLa and MCF7 was performed in order to 
[15] 
 
characterize its localization and suggest a potential function, especially with regard to MYOVI 
localization.  
MCF7 is a human breast adenocarcinoma cell line initially derived in 1970 from malignant 
adenocarcinoma.  Within the breast cancer field it is the most studied cell line due its stability in 
adherent culture, fast replicative prowess and genomic stability in comparison to other cancer 
cell lines which exhibit large variations in chromosome number. This cell line has preserved its 
functionality to process estradiol via estrogen receptor alpha (ERg) and is therefore extremely 
useful in monitoring hormone induced expression changes and resistance. They have lost 
expression of DAB2 and hence are a good target for the study of the ESR1-DAB2 fusion as any 
DAB2 epitope picked up through biochemical assays will only be provided by the DAB2 portion 
of the fusion and not endogenous expression. (39) 
The HeLa cell line, originally derived from Henrietta Lacks’ cervical cancer in 1951, is one of 
the most used cell lines in biomedical science. These cells exhibit high numbers of chromosomes 
due to replicative errors (instead of 46 chromosomes they often have 76-80 chromosomes) but 
are advantageous in cell work as they grow extremely fast. This high proliferative rate can be 
attributed to the 10-50 copies of HPV18 genome and the E6 and E7 oncoproteins from the 
human papillomavirus (HPV) (91). Replicative errors are due to the insertion of a HPV genome 
near the myc proto-oncogene in the genome resulting in rapid and endless replication as a result 
of the activated expression of telomerase (40). Unlike MCF7 HeLa have conserved the 
expression of DAB2 but instead have lost the expression of ER. Using the differences between 
the two cell lines in this way allows the functionality of MYOVI to be compared in both hypoxic 
and transfected conditions.   
The use of both cell lines allows for a comparative analysis of ESR1-DAB2’s functionality in 
both ER+ ad ER- cell lines and could shed some light on why this specific mutation favors 
MBC. 
The extrinsic stressor, hypoxia, is seen in patients with higher levels of metastasis and also 
results in resistance to radiotherapy and chemotherapy in some patients. Study of its effects is 
invaluable to examine the endogenous expression of MYOVI and ERg/DAB2 in MCF7 and HeLa 




2.0: Materials and methods:  
2.1: Cell culture  
HeLa (ECACC 9301013) and MCF7 (ECACC 86012803) cell lines were cultured in Gibco 
MEM media supplemented with 10% fetal bovine serum and a combination antibiotic composed 
of 100 units/ml penicillin and 100µg ml-1 streptomycin (MEM-complete). Sterile plates or flasks 
were incubated at 37°C with 5% CO2. Adherent cells are washed with sterile and filtered PBS 
before being trypsinised with trypsin 0.05% EDTA. Following 5 further minutes of incubation 
cells detach from plastic surface and can be counted. Cells are typically grown to 70-80% 
confluency and were only used for experiments between passages 3 and 25.  
2.2: Transfections  
Transfections were performed in 24 well plates on both MCF7 and HeLa cell lines using 
Lipofectamine 2000 (Invitrogen) as the transfection reagent. 500ng of the ESR1-Dab2 plasmid 
was added to 1µl of lipofectamine in opti-MEM and applied to the cells in antibiotic deficient 
media. The media was then changed back to complete after 5 hours and the cells were fixed after 
48 hours.  
Electroporation was also employed in which 2.5x106 cells were resuspended in Gibco opti-MEM 
media with 25µg/ml DNA in 0.2cm cuvettes. Exponential decay mode was selected where the 
voltage was set to 300, capacitance at 500uF and the decay curve registered between 4.5 and 
4.8ms pulse time. The sample was then immediately seeded into a 6 well plate or 24 well plate 
with pre-warmed MEM-complete media.  
 
2.3: Immunofluorescence (IF) 
Growth medium was removed from transfected and hypoxic cells before washing with PBS. In 
the case of hypoxic cells all stages of fixation were performed within the sealed hood at 37°C to 
prevent a reversion to normal metabolic function upon exposure to oxygen. Transfected samples 
were fixed at room temperature. 4% (w/v) paraformaldehyde was applied to wells for 15 minutes 
followed by quenching using 50mM ammonium chloride for a further 15 minutes. The nuclear 
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DNA was stained via a 10 minute incubation using 1µg ml-1 Hoechst 33342 (Thermofisher) in 
PBS.  
Post fixation cells were permeabilized and blocked with 3% (w/v) BSA in PBS, supplemented 
with 0.1%(w/v) Triton X-100, before being covered and incubated for 1.5 hours in the primary 
antibody at the appropriate dilution in 3% (w/v) BSA in PBS. The cover slips were then washed 
in 0.2%(w/v) BSA 0.05%(w/v) Triton X-100 in PBS three times and the secondary antibody was 
applied  at the appropriate dilution in 3% (w/v) BSA in PBS, before covering and incubating for 
1 hour. All steps post-fixation were performed at room temperature for transfected and hypoxic 
experiments. 
All antibodies used for experiments are listed with their corresponding optimized dilutions. 
 
Primary antibodies used: 
• Abcam anti-Dab2 antibody (ab88590) mouse polyclonal 1:100 dilution 
• Abcam anti-HA tag antibody (ab18181) mouse monoclonal 1:200 dilution 
• Sigma anti-MYO6 antibody (HPA035483) rabbit polyclonal 1:200 dilution 
• Anti-ERg antibody (sc-8002: santa cruz biotechnology) mouse monoclonal 1:100 dilution   
Secondary antibodies:  
• Anti- mouse Alexa 488 (green) antibody  
• Anti- rabbit alexa 555 1:500 dilution 
The cover slips were washed once again with PBS before mounting onto slides using Mowiol 
(10% (w/v) mowiol, 25% (w/v) glycerol, 0.2M Tris-HCL, pH8.5) supplemented with the 
antifading reagent DABCO (Sigma #D-2522).  
 
2.4: RNA extraction and PCR  
• RNA extraction:  
1ml of cold trizol was added to 1x106 cells before incubation at room temperature for 5 
minutes. 200µl of chloroform was added to the cell lysate and incubated for 2 further minutes 
at room temperature before centrifugation at 12000g for 15 minutes at 4°C.  
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The top aqueous phase (containing RNA) was transferred to a clean microcentrifuge tube and 
500µ of isopropanol was added then incubated for 10 minutes. The sample was centrifuged at 
12000g for 10 minutes at 4°C. The supernatant was disarded and pellet resuspended in 1ml 
of 75% ethanol then vortexed and centrifuged for 5 minutes at 7500g at 4°C. The supernatant 
was once again discarded and pellet washed with ethanol again before being left to air dry in 
a fume hood. Pellet was then resuspended in 20-30µl of RNAse-free water and incubated on 
a heat block at 60°C for 15 minutes.  
The RNA concentration was then measured using a nanodrop. 500ng/ul final concentration 
was achieved by diluting RNA samples with water. 1ul was then carried forward into cDNA 
synthesis. 
• cDNA synthesis:  
cDNA synthesis was performed using abm’s onescript cDNA synthesis kit and protocol.  
• PCR:  
PCR was performed using Pfu Phusion protocol supplied by new England biolabs. cDNA 
was diluted to a 1/10 mix and a 100mM stock of each primer was diluted to 10mM. The total 
reaction volume was adjusted to be 20µl. Samples were loaded into techne 3 prime personal 
thermal cycler where the cycling programme was as follows:  
Denaturation: 98°C, 30 seconds 
25-35 cycles: 98°C, 5 seconds 
Annealing: 72°C 15-30 seconds/kb 
Final extension: 72°C, 10 minutes 
Hold: 5°C  
• qPCR:  
qPCR was performed on cDNA samples (1ng) obtained from onescript kit using green-2-go 
qPCFR mastermix supplied by biobasic. The expected band size of ESR1 is 51bp. 
2.5: Hypoxic culture:  
[19] 
 
Cell lines were seeded into 24 well plates at a stock concentration of 2.3x105 cells/ml. Incubation 
was undertaken for 5 and 24 hours where cells were fixed or scraped within the hypoxic hood. 
Conditions were set to 37°C, 0% O2 substituted with N2 and 5% CO2. 
2.6: Immunoblotting 
MCF7 and HeLa cells were scraped off the culture dishes and centrifuged for 10 minutes at 
500xg to form a pellet at 4°C. The cell pellets were then lysed using a lysis buffer comprised of 
stock reagents 4x NuPAGE SDS- sample buffer (thermofisher scientific), 1x PBS and 1 M DTT 
in a 4:4:2 ratio before being run on an 8% acrylamide gel, along with PageRuler Plus Prestained 
Protein Ladder. The gel was then immersed in running buffer with 1% methanol. The running 
buffer was diluted to 1x from a 10x tris-glycine SDS stock solution (25mM Tris base, 192mM 
glycine, 1% SDS at pH 8.3).  
The PVDF membrane was activated by 100% methanol soaking for 1 minute before being rinse 
thoroughly and submerged in transfer buffer (NuPage transfer buffer by thermofisher scientific) 
on a rocker for 5 minutes. The fiber pads were also soaked in transfer buffer before being stacked 
in the transfer pad. Once the proteins have been transferred onto the PVDF membrane it was 
placed in blocking methanol (10%) for 5 minutes and washed before being soaked in blocking 
buffer (5% milk in TBS enriched with 0.1% tween) for a minimum of 1 hour. The primary 
antibody is then added to the blot in blocking buffer at the appropriate dilution and incubated on 
a rocker for 1.5 hours. The membrane was then washed with washing buffer (1% milk in TBS, 
enriched with 0.1% tween) three times at 10 minute intervals before the secondary antibody was 
applied in blocking buffer at the appropriate dilution and incubated on the rocker for 1 hour.  
Primary antibodies:  
• Sigma anti-MYO6 antibody (HPA035483) rabbit polyclonal 1:500 dilution  
• Anti-ERg antibody (sc-8002: santa cruz biotechnology) mouse monoclonal 1:100 dilution   
• Abcam anti-Dab2 antibody (ab88590) mouse polyclonal 1:1000 dilution 
• Abcam anti-HA tag antibody (ab18181) mouse monoclonal 1:1000 dilution 
Secondary antibodies:  
• Abcam Goat Anti-mouse IgG (Hrp) (ab97023) 1:15000 dilution 
• Abcam goat anti-rabbit IgG (Hrp) (ab6721) 1:15000 dilution 
[20] 
 
To image the secondary antibodies ECL western blotting detector reagents (Invitrogen) were 
used following the product protocol and blots were then imaged using Syngene Gbox which 
acquired images through Genesys software. 
 
2.7: Imaging 
Initial experimental cell imaging was performed using the Zeiss confocal microscope where 
mounted samples were illuminated with LSM 880 lazer light source using the appropriate filters. 
Zen Black was then used capture and save images images. The 100x lens was used to obtain 
images where a z-stack through the nucleus was used to obtain cell slices and the middle slice 
was used. 
Further imaging was executed using the Olympus BX-61 epifluorescence microscope equipped 
with cooled CCD camera using SmartCapture 3 software (digital scientific, UK) to capture and 
save images.  
2.8: Image analysis 
All images were analyzed using imageJ. Image quantification was performed by calculating the 
corrected total cell fluorescence (CTCF);  系劇系繋 噺 岫件券建結訣堅欠建結穴 穴結券嫌件建検伐 岫欠堅結欠 剣血 嫌結健結潔建結穴 潔結健健 抜 兼結欠券 血健憲剣堅結嫌潔結券潔結 剣血 決欠潔倦訣堅剣憲券穴 堅結欠穴件券訣嫌岻 
The mean fluorescence was calculated from the CTCF of three images, for both the red and 
green channels, where the minimum and maximum brightness and contrast was set to the same 
values.  
Standard deviation of the samples was calculated in excel using the CTCF’s obtained for each 







3.1: Optimizing exogenous expression of ESR1-DAB2 fusion in HeLa and MCF7 cells 
Previous research into the functionality of the ESR1-DAB2 fusion has exclusively been 
performed in HEK293 cells (human embryonic kidney cell line). Therefore, in order to acquire 
more informative results, it would be useful to investigate the behavior of this fusion protein in 
other cancer cell lines. MCF7, like HEK293, have lost the endogenous expression of DAB2 but 
retain the expression of ESR1. HeLa however, express endogenous DAB2, but have lost 
expression of ESR1. For these reasons HeLa and MCF7 were chosen as representative models to 
observe the exogenous expression of the fusion protein. 
The ESR1-DAB2 plasmid is relatively large and therefore this can result in less efficient and 
effective transfection via normal practice. Consequently, this section mainly focuses on 
comparing lipid-based transfection and electroporation transfection to determine the most 
effective method for resultant expression of ESR1-Dab2 within HeLa and MCF7.  
We hypothesized that the two proteins may interact as Dab2 is a binding partner of MYOVI. 
Therefore, double IF (dIF) was performed to observe the fusion and MYOVI simultaneously 
within samples, allowing any co-localization to be detected. In theory, due to the loss of 
endogenous ERg in HeLa, the control samples express no protein for the anti-ERg antibody to 
bind to and hence there will be no fluorescent signal. ESR1-DAB2 transfected HeLa cells should 
show a signal when probed for ERg, which we could identify as solely induced by the presence 
of the fusion protein. Similarly in MCF7, probing with an anti-DAB2 antibody would only elicit 
a signal from the resultant fusion protein, as this cell line has lost the endogenous expression of 
DAB2. The confocal images in figure 1 acted to test this theory and method of detection where 
electroporated MCF7 were probed with anti-DAB2 and anti-MYOVI primary antibodies while 




















In the process of these optimizations it should be mentioned that Figure 1 highlighted the lack of 
MYOVI fluorescence signal using the Alexa647 antibody. Due to the emission spectra of this 
fluorophore, we were limited to use of the confocal microscope, which still seemed to be unable 
to display a strong signal. As a result of this observation, future experiments employed Alexa555 
as a secondary antibody to image MYOVI in transfections.  
Examining protein levels within HeLa and MCF7 
Microscopy is very useful in visualizing protein localization within cell lines, but is limited in 
terms of quantifying the amount of protein within the cell and nuclear compartment. Therefore, 
Figure 1:  Confocal images of 
electroporated HeLa and MCF7 
with ESR1-DAB2 where double IF 
was performed in order to image 
MYOVI and ESR1-Dab2 via anti-
Erg in HeLa or anti-Dab2 in 
MCF7. Alexa647 and Alexa488 
secondary antibodies were used 
respectively (HeLa Scale: 14.80 




western blots were performed to provide a more reliable indication of the levels of expressed 
MYOVI and ESR1-DAB2 within the cell lines which could then be supported by fluorescence 











In order to characterize whether there was any change in MYOVI expression levels influenced 
by the introduction of ESR1-DAB2, western blotting was performed from lysed electroporated 
samples. Figure 2 shows the initial control blots using non-electroporated MCF7 and HeLa 
samples in order to ensure the method was optimized for use of ER and DAB2 antibodies and 
both cell lines. While the actin blot displays very dirty bands, we can obtain a distinct band using 
20µl and 30µl of the sample and the band intensity shows a proportional increase when more 
sample is loaded. Figure 2B and C show that endogenous expression of ERü and DAB2, in 
Control Western Blots of non-transfected MCF7 and HeLa cells 
Figure 2: A – MCF7 cell lysate was run on a 8% gel before being transferred onto a western blot and 
probed for く-actin as a standard in order to confirm the western protocol was effective. B- MCF7 non-
transfected cell lysate was run on an 8% gel and then probed for ERg in order to optimize the amount of 
antibody required in order to produce a clear band. C- HeLa non-transfected cell lysate was run on an 8% 
gel and probed to optimize the amount of antibody needed to display a defined band with minimal 
background/non-specific binding.  
[24] 
 
MCF7 and HeLa respectively, is easily detected in a western blot by probing with these two 
antibodies. 
Positive controls were then performed on lysed electroporated MCF7 and HeLa samples, shown 
in Figure 3, to examine if the endogenous expression of these proteins was affected by the 
presence of the fusion and determine if endogenous expression was altered as a result of 
transfection stress. In the MCF7 left hand blot ERg appears as a band at ~65kDa and in the right 
hand HeLa blot DAB2 appears slightly below that expected at ~85kDa and seems to exhibit a 
weaker signal in ESR1-DAB2 transfected HeLa compared to the control. It was made clear from 
the HeLa blot that a higher volume (30µl) of the electroporated sample would need to be loaded 






Figure 4 shows the stripped western blot from Figure 3 which was then re-probed with MYOVI 
and ERg antibodies. Unfortunately this was unsuccessful in revealing a MYOVI band or an ERg 
band. Figure 5 followed the same procedure but was re-probed with DAB2 antibody instead of 
ERg. The western shows a band in both control and ESR1-DAB2 samples at ~150kDa, 
consistent with the presence of MYOVI, however it is not clear that the levels of MYOVI vary 
Figure 3: Electroporated cell lysates from MCF7 and HeLa were probed with ERg and Dab2 antibodies 
respectively as a positive control to determine optimum load to produce a clear band for endogenous 
protein and ensure sample viability for further western blotting. 
Control Western Blots of ESR1-Dab2 transfected MCF7 and HeLa cells 
[25] 
 
between not only increasing the volume loaded but also between the control and the ESR1-


















Unfortunately due to protein folding and the partial loss of epitopes within the fusion of the 
ESR1 and DAB2 genes result in ERg and DAB2 antibodies not effectively binding and therefore 
Figure 4: Reprobed western blot for Myosin VI and ERg (after stripping) of electroporated cell lysates 
from HeLa control and ESR1-DAB2 samples.  
Figure 5: Reprobed western blot for myosin VI and DAB2 (after stripping) of electroporated cell 
lysates from MCF7 control and ESR1-DAB2 samples. 
[26] 
 
in microscopy and western blotting the signal was not sufficient to confirm transfection. This 
was supported by the absence of the fusion in qPCR experiments shown in the supplementary 
material as the primers used (for ESR1 and DAB2 respectively) could not bind to the fusion. The 
preliminary transfections highlighted that these two antibodies were not viable to use in order to 
detect the fusion protein within samples. Hence, we had to determine another route to 
specifically detect the fusion, the most logical being to utilize the presence of the HA tag within 
the fusion. An anti-HA antibody was acquired and then used for all further dIF probing of 
samples, however westerns were unable to be performed due to our inability to acquire a HA 
positive sample in the time remaining. Microscopy using the HA antibody required additional 
optimization typically associated with utilizing a new antibody, ensuring that the previous dIF 
protocol was altered to elicit a clear signal. The following section displays the results of ESR1-
Dab2 transfection via electroporation and lipofectamine methods where an anti-HA antibody is 





























Figure 6: Images of HeLa cells transfected with ESR1-DAB2 plasmid using lipofectamine or 
electroporation. Immunofluorescence was performed post fixation using an anti-HA primary 
antibody alongside an anti-MYOVI antibody with alexa488 and 555 secondary antibodies 
respectively. Areas of interest are marked within the nucleus using imageJ to compare localization 
of both proteins in control and transfected states. (Scale: 15.215 pixels/µm) 
Microscopy of ESR1-DAB2 transfected HeLa cell line 
[28] 
 
Figure 6 shows transfection of the ESR1-DAB2 plasmid in HeLa using two common methods of 
transfection. In this cell line lipofectamine, a lipid based transfection method which induces the 
formation of liposome to ensure delivery of the plasmid, seems to result in more effective 
transfection as there is a visibly stronger HA signal. The HA antibody is infamously difficult to 
accurately image which is supported by the presence of a signal in both lipofectamine and 
electroporation controls. It is clear however that the HA signal is stronger in transfected cells and 
localized strongly to the periphery of the nuclear membrane as well as a small population of the 
protein displaying fluorescence inside the nucleus.  
While the fluorescence intensity of MYOVI does not seem to vary between control and 
transfected samples, there is a definitive difference in the localization of the protein suggesting 
an effect of the presence of ESR1-DAB2 fusion on MYOVI distribution. MYOVI seems to 
localize strongly to the immediate periphery of the nucleus in both transfection conditions, with a 
reduction of the nuclear population seen in the transfected samples. Interestingly an unusual 
structure is visible in the electroporation sample which seems to span the center of the nucleus in 
a non-dividing cell and was observed in 33% of ESR1-DAB2 expressing cells. 
Due to the nature of microscopy images it is difficult to use this data alone to arrive at a 
conclusion. Each individual cell may respond differently and fluorescence between cells can 
vary greatly. Therefore, in order to quantify this data and provide a more inclusive view of the 
effect of lipofectamine and electroporation transfections of ESR1-DAB2 the whole cell 
fluorescence intensity was measured from multiple cells within the sample to obtain a mean and 





























A ｪヴ;ヮｴ デﾗ ゲｴﾗ┘ デｴW ┗;ヴｷ;デｷﾗﾐ ｷﾐ ヴWﾉ;デｷ┗W aﾉﾗ┌ヴWゲIWﾐIW ﾗa M┞ﾗゲｷﾐ VI 






Figure 7 can be used alongside Figure 6 to infer the change in MYOVI and HA expression in 
HeLa between control and transfected samples. Reading from the bar graph, in HeLa there is 
littl e to no variation in the total cell MYOVI fluorescence between control and transfected 
samples in both methods of transfection. However, it is interesting to note that electroporation 
seems to cause a response that may be stress related seen in the elevation of MYOVI 
fluorescence in the control compared to the lipofectamine method. Using the images in Figure 6 
we can say that while this fluorescence is as high as that observed in the transfected sample, the 
signal pattern of MYOVI changes within the nucleus in transfected samples, with an increase in 
Figure 7: A Bar graph to show the quantification of mean fluorescence intensity in HeLa for both MYOVI 
and HA from each sample analyzed using imageJ. The standard deviation was also calculated to allow for 
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cytoplasmic signal suggesting altered function of MYOVI. HA fluorescence can be seen to 
increase slightly in transfected samples but the change in fluorescence seems minute when the 
error bars are taken into consideration. However, using the quantified data alongside the 




Figure 8 provides further insight into the change in localization of MYOVI and HA in both 
lipofectamine and electroporation transfections. It is clear that the method of transfection does 
affect the distribution of both proteins however in both there is an increase of HA within the 
Figure 8: A Bar graph to show the quantification of fluorescence intensity in HeLa nuclei under 
transfection with lipofectamine and electroporation. The data corresponds directly to the marked
nuclear zones seen in the microscopy images (Fig.6). 
[31] 
 
nucleus suggesting that the ESR1-DAB2 plasmid is present post transfection. Lipofectamine 
exhibits a more drastic increase in fluorescence between the control and the ESR1-DAB2 
expressing cells within HeLa suggesting that this method is more effective than electroporation 
in allowing the plasmid to infiltrate this cell line. The levels of MYOVI seem to decrease in 
lipofectamine transfections; this suggests that while the total fluorescence increases (Fig.7), the 
population of MYOVI migrates to the nuclear periphery which is seen unanimously in ESR1-
DAB2 expressing cells. In electroporation MYOVI fluorescence within the nucleus seems to be 
level and interestingly similar to the level of HA fluorescence in ESR1-Dab2 expressing cells. 
However HeLa seems to have poor transfection efficiency using this method and therefore this 





























Figure 9 displays the images collected in the MCF7 breast cancer cell line after transfection with 
ESR1-DAB2 using lipofectamine and electroporation techniques.  Visually there seems to be an 
Figure 9: Images of transfection of ESR1-Dab2 plasmid in MCF7 using both lipofectamine and 
electroporation. Immunofluorescence was performed post fixation using an anti-HA primary antibody 
alongside an anti-MYOVI antibody with alexa488 and 555 secondary antibodies respectively. Areas of 
interest are marked within the nucleus using imageJ to compare localization of both proteins in control 
and transfected states. (Scale: 15.215 pixels/µm) 
Microscopy of ESR1-DAB2 transfected MCF7 cell line 
[33] 
 
increase in the intensity of HA fluorescence suggesting that transfection was successful in this 
cell line using both transfection techniques.  Examining first the lipofectamine transfected 
images, both the total and nuclear HA fluorescence increases when comparing the control and 
ESR1-DAB2 samples, with a large population of the ESR1-DAB2 protein seen to be residing 
within the nucleus. Transfection via electroporation also shows an increase in HA fluorescence, 
however the ESR1-DAB2 protein seems to collect on the nuclear periphery and not infiltrate the 
nucleus as vehemently as that seen by lipofectamine. Hence there seems to be a variation in 
localization and potentially then function of ESR1-DAB2 depending on the method of entry of 
the plasmid; using lipofectamine HA localizes strongly within the nucleus and the periphery 
whereas in electroporation the majority of the population of ESR1-DAB2 can be seen to localize 
at the nuclear periphery.  
Once again as seen in Figure 6 in the HeLa cell line, total cell MYOVI fluorescence seems to 
remain constant, suggesting that expression of this motor protein is stable in MCF7 even after 
transfection stress. Figure 9 does reveal that localization is altered in both transfection methods 
between the control sample and the ESR1-DAB2 expressing cells. Lipofectamine transfection 
maintains a population of MYOVI within the nucleus seen in both the control and the ESR1-
DAB2 expressing cells, however there seems to be a larger aggregation of MYOVI at the nuclear 
periphery visualized by the stronger fluorescent signal. In comparison electroporation seems to 
result in a smaller nuclear population of MYOVI in the control sample, so it is interesting to see 
the appearance of a similar structure to that observed in Figure 6 with HeLa electroporation in 
the ESR1-DAB2 expressing MCF7. Once again, the nucleus indicates that the cell is non-
dividing and MYOVI also seems to collect at the periphery of the nuclear membrane with a less 
diffuse signal than the control.  
From the merged images MYOVI also seems to co-localize with the ESR1-DAB2 fusion. This 
accounts for the different MYOVI localization patterns in lipofectamine and electroporated cells 
as the localization of the ESR1-DAB2 fusion determines the positioning of MYOVI within 
MCF7. 
These images were further analyzed in order to quantify the results into numerical data, allowing 
a mean to be calculated from images of three separate cells under these conditions and this can 







From Figure 10 it is clear to see that the relative fluorescence fluctuates more in transfections 
using lipofectamine due to the size of the error bars. This suggests that in the case of MCF7, 
electroporation provides a more reliable set of data where both HA and MYOVI fluorescence in 
an individual cell is more closely representative of the whole population, where lipofectamine 
results in a large range of fluorescence and hence expression. Nevertheless, in both methods the 
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Figure 10: A Bar graph to show the quantification of mean fluorescence intensity in MCF7 for both MYOVI
and HA from each sample 3 images of single cells from separate slides were analysed for each condition 
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expressing cells suggesting successful transfection and expression of ESR1-Dab2 within this cell 
line.  Total cell MYOVI fluorescence is also seen to increase post transfection with 
lipofectamine and via electroporation. In both lipofectamine and electroporated ESR1-Dab2 
expressing samples the total cell fluorescence of HA and MYOVI seem to be very similar 
therefore the localization of ESR1-Dab2 and MYOVI proteins was further quantified from 





Figure 11: A Bar graph to show the quantification of fluorescence intensity in MCF7 nuclei post 
transfection with lipofectamine and electroporation in control and ESR1-Dab2 expressing samples. 
The data includes the marked nuclear zones seen in the microscopy images (Fig.9) and nuclear 
zones isolated from two other cells for each condition. 
[36] 
 
Comparing the data from Figure 10 and Figure 11 allows the localization of ESR1-DAB2 and 
MYOVI to be considered. During lipofectamine transfections, Figure 11 shows the population of 
ESR1-DAB2 within the nucleus increases drastically, visualized by the peak in HA fluorescence, 
whereas the levels of MYOVI seem to remain stable despite the increase in fluorescence seen in 
Fig.10. This suggests that MYOVI remains on the nuclear periphery and is correlates with the 
pattern of fluorescence observed in the microscopy images (Fig.9). From Figure 11, transfection 
by electroporation results in a negligible decrease in HA fluorescence within the nucleus of 
ESR1-DAB2 expressing cells. This is paired with a small decrease in MYOVI within the nucleus 
revealing that in addition to both proteins exhibiting similar fluorescence levels (Fig.10) they 
both seem to be confined to functions at the nuclear periphery and cytoplasm of MCF7 cells as
















3.1C: Comparisson between MCF7 and HeLa 
As HeLa and MCF7 cell lines were selected based on their varying endogenous expression 
profiles,  it is integral to compare the effect of ESR1-DAB2 transfection between the two to 
consolidate the differences in lipofectamine and electroporation transfection of this plasmid, 
providing some insight into the functionality of ESR1-DAB2 and the resultant localization of 
MYOVI in response to this intrinsic stressor. Figure 12 shows the data collected in sections 3.1A 
and 31.B side by side for ease of interpretation and comparison of quantified fluorescence 
between the two cell lines.  
Figure 12A shows the mean relative total cell fluorescence of HA and MYOVI in transfections 
exclusively involving lipofectamine. In the control samples MCF7 and HeLa have similar levels 
of MYOVI fluorescence . HA fluorescence is higher in the MCF7 control sample than that in 
HeLa; however, in the ESR1-Dab2 samples this level seems to double in both cases. HeLa 
ESR1-Dab2 HA mean relative fluorescence seems to mirror the control levels in MCF7. 
Transfection using lipofectamine results in a dramatic increase in MYOVI levels within ESR1-
DAB2 expressing MCF7, over double the value seen in ESR1-DAB2 expressing HeLa. Figure 
12B shows the mean relative total cell fluorescence of HA and MYOVI following transfections 
by electroporation. Similarly to 12A MCF7 exhibit a much higher background HA signal in the 
control sample than HeLa, however the same pattern is observed as HA mean fluorescence 
doubles from the control to ESR1-Dab2 expressing cells. Interestingly the level of MYOVI 
fluorescence is very similar in both MCF7 and HeLa control samples, as well as the HeLa ESR1-
DAB2 sample, and in tune with the lipofectamine results (Fig.12A) MYOVI is seen to have 
increased fluorescence in MCF7 expressing ESR1-DAB2. 
 Figure 12C allows all the data collected to be compared and from this we can see that the peaks 
of MYOVI fluorescence observed previously in MCF7 expressing ESR1-DAB2 (Fig.12A and 
Fig.12B) are at a very similar level in both lipofectamine and electroporation transfections. The 
same pattern can be observed between electroporated and lipofectamine transfected HeLa, 
suggesting that although localization seems to vary (Fig.6 and Fig.9), the effect of ESR1-DAB2 
expression, regardless of the method of transfection, causes a standardized increase of MYOVI 





Figure 12: A- Mean relative fluorescence under lipofectamine transfections in both MCF7 and HeLa cell 
lines. B- Mean relative fluorescence under electroporation transfections in both MCF7 and HeLa cell 
lines. C- A cumulative graph of all the quantified data from imaged experiments described and imaged 
under section 3.1 involving transfection with ESR1-Dab2. All data was acquired using imageJ and the 
mean was calculated from 3 images for each condition. Error bars were calculated from raw data 
collected using standard deviation to calculate standard error. 




Overall figure 12C shows that electroporation is a more reliable method of transfection for this 
large plasmid as the standard deviation covers a smaller range on either side of the mean 
fluorescence, indicating that the population of ESR1-DAB2 cells share a phenotype whereas 
lipofectamine transfections result in a broad range of fluorescence within the population of 
transfected cells.  Despite this, electroporation in HeLa is not as effective as in MCF7 as shown 
by the incremental increase in HA and MYOVI fluorescence. In general the MCF7 cell line 
responds positively to transfection with ESR1-DAB2 whereas the data from HeLa seems to 
overlap between the control and transfected, hence is inconclusive and gives a limited insight 


















3.2:Endogenous protein distribution in HeLa and MCF7 exposed to hypoxia  
Exposing cells to hypoxia allows a more realistic view of protein expression and localization 
within a tumour mass microenvironment, before angiogenesis is activated to supply the cells 
with oxygen. This section therefore focuses on the localization of MYOVI and its 
binding/interacting proteins DAB2 and ERg within HeLa and MCF7 respectively over varying 
time periods of exposure to hypoxia. This may provide some insight into how these two cell lines 
survive in hypoxic states.  





Figure 13: Microscopy of HeLa cells under 0, 5 and 24 hours hypoxia where immunofluorescence was 
used to visualize DAB2 and MYOVI localization and intensity with alexa488 and 555 respectively. Areas 
of interest within the nucleus are marked for further quantification and focused analysis.  
Microscopy of HeLa cell line exposed to hypoxia 
[41] 
 
The microscopy images seen in Figure 13 display the localization of endogenous MYOVI and 
DAB2 under varying time frames of hypoxic stress in HeLa cells. At a glance there seems to be 
very little difference between the control and the 5 hour 0% oxygen, 5% CO2 condition, but the 
24 hour sample shows dramatic change to the cells morphology and phenotype. Examination 
under the microscope displayed mass cell death in HeLa after 24 hours of hypoxic stress and the 
cells became filamentous in nature. This is visualized above as the nucleus is rounded where 
typically it would appear oval in shape such as that seen in the control and 5 hour samples. Dab2 
can be seen to infiltrate the nucleus, displaying minimal cytoplasmic localization and this seems 
to be paired with MYOVI nuclear migration.  
These images are limited in inferring the true change in localization and expression, therefore 
each sample was analyzed to collect quantit tive data which is more representative of the 
population of cells in this condition, as opposed to a single image of a single cell.  
Figure 14A displays the mean total cell fluorescence of MYOVI and Dab2 in HeLa during 
hypoxia. While the standard deviation overlaps for all samples, the quantification of data from 
several microscopy images allows a more representative result and conclusion to be formed. It is 
interesting to see that both Dab2 and MYOVI fluorescence levels peak at 5 hours in HeLa, 
before descending again at 24 hours to levels similar to that seen in the control samples. MYOVI 
total fluorescence doubles in this state in comparison to the control which was not previously 
evident in figure 13.  
Figure 14B focuses on only the nuclear fluorescence of Dab2 and MYOVI within HeLa and 
shows a steady increase in MYOVI fluorescence intensity as the cells are exposed to hypoxia for 
longer. Furthermore, Dab2 nuclear fluorescence seems to double at 5 hours under hypoxia but 
still remains at a relatively low level in comparison to the massive peak seen in the 24 hour 
hypoxia sample. Using the data from figure 14B alongside the 24 hour microscopy image in 
Figure 13, the cell is not healthy and hence the spike in nuclear proteins could be attributed to the 
death of cells. Therefore, the most relevant data to examine in HeLa is the 5 hour hypoxia 
sample which shows increased mean Dab2 and MYOVI total fluorescence compared to the 
















































































Figure 14: A- Quantified data from microscopy images acquired where the mean and standard deviation of 
fluorescence of MYOVI and DAB2 were calculated from 3 single cell microscopy images for each condition in 
HeLa. B- Quantified data from zones marked in microscopy images (Fig.13) and two further nuclei for each 





Figure 15 displays a western blot of cell lysate from each condition probed for MYOVI and 
DAB2. There seem to be bands present in the control sample and with 30µl of the 5 hour 
hypoxia cell lysate at ~100kDa indicating that this is the Dab2 band, however it is not clear that 
there is a difference in the amount of DAB2 present in these loads. Additionally, MYOVI does 
not present a band for any of these samples; therefore, further optimization is required to obtain a 
definitive result. Furthermore, the loading amounts need to be optimized to account for hypoxia 
















Figure 15: Western Blot analysis of HeLa cell lysate from cells exposed to hypoxia 
for 0 (control), 5 and 24 hours. 30µl of control sample was loaded and two volumes 




3.2B: Distribution of MYOVI and ERü in MCF7 exposed to Hypoxia 
The MCF7 cell line seemed to be more robust even after up to 24 hours exposure to hypoxia with 
minimal cell death and sustained 70-90% confluency. The phenotype did change mildly as cells 
became more adhesive and clumped together in masses, a typical reaction seen in MCF7 under 
stress, but as shown in Figure 16 the nucleus remained rounded in all experiments and the 
cellular membranes remained intact.  
The control images show that ER is confined very strongly to the nucleus with no fluorescence 
displayed in the surrounding cytoplasm. MYOVI fluorescence however is diffuse throughout the 
cell. After 5 hours under hypoxia the ER fluorescence remains localized strictly to the nucleus 
while MYOVI seems to alter from the control with a population of this protein migrating into the 
nucleus and concentrating on the internal and external nuclear membrane.  
 
 Figure 16: Microscopy of MCF7 cells under 0, 5 and 24 hours hypoxia where immunofluorescence 
was used to visualize ER and MYOVI localization and intensity with alexa488 and 555 
respectively. 




Interestingly there seems to be a clump of high fluorescence from MYOVI within the nucleus 
that is observed in both the 5 hour and 24 hour hypoxia samples. The 24 hour hypoxia images 
show reduced fluorescence from ERg while it is still confined to mainly the nucleus. MYOVI 
now shows an increased nuclear population as well as high fluorescence at apical membranes of 
the cell. The merged images for the 5 hour and 24 hour hypoxia samples show co-localization of 
nuclear MYOVI and ERg.  
Figure 17 shows the nuclear fluorescence of MYOVI in these samples and indicates that there is 
an increase in the population of nuclear MYOVI as the hypoxia is maintained for longer amounts 
of time in MCF7.  
Quantified data from a collection of microscopy images of MCF7 under hypoxia is displayed in 
Figure 18. While the nuclear fluorescence is seen to increase in MCF7 with increasing duration 
of hypoxia the mean total fluorescence of MYOVI observed within this cell line seems to be 
steady. It should be noted that the standard deviation is the largest at 5 hours suggesting that the 
MYOVI fluorescence at this stage exhibits a large range between cell samples measured and 











































Furthermore, the mean level of fluorescence of ERg within MCF7 remains relatively stable until 
exposed to 24 hour hypoxia where it is seen to decrease. As the signal is confined to the nucleus 
(Fig16) there was no need to measure the change in nuclear fluorescence to compare between 
samples as localization of ERg seems to be unaffected by hypoxia.   
In a further attempt to quantify the amount of MYOVI and ERg expressed during hypoxia a 
western blot was performed as show in Figure 19. The MYOVI band appear at ~150kDa and is 
seen strongly in the control and 24 hour samples. When comparing the 0 hour 15µl load to the 24 
hour 15µl load it seems that the intensity of the band has doubled. Unfortunately there is no band 
visible in the 5 hour samples, however the dark band at ~100kDa does resemble that of the other 
MYOVI bands but may be due to a load or sample preparation error and would need to be 
repeated. 
 
Figure 18: Quantified data from microscopic images displaying the mean total cell fluorescenc  of MYOVI 
and ER in MCF7 over varying time spans under hypoxia. Standard deviation was also calculated from the 
raw data collected before calculating standard error from several images of each condition. Three cells from 








The ERg band appears on the western at ~85kDa and seems to be more pronounced in the 24 
hour samples than the 0 hour samples. Unfortunately, the 5 hour sample is not clear but the dark 
bands present do appear in line with ~85kDa indicating that it is potentially ERg showing up. 
The intensity of the band is dramatically higher than that seen in 0 or 24 hours but, as with 
MYOVI the 5 hour time point would need to be repeated. 
The western blot suggests that there is a change in expression of MYOVI and ERg induced by 
hypoxia where there is an upregulation of the production of these proteins within MCF7, this was 





Figure 19: Western Blot analysis of MCF7 cell lysate from cells exposed to hypoxia for 0 (control), 5 and 
24 hours. Two volumes of each of the hypoxic sample were loaded to ensure the presence of a visible 
band. Full short and long exposure blots are displayed in the supplementary figures. 
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3.2C: Comparison of endogenous MYOVI and ERü/Dab2 distribution in response to hypoxia in 
MCF7 and HeLa respectively 
Comparing the effect of the extrinsic stressor hypoxia between the MCF7 and HeLa cell lines is 
invaluable in order to infer the pathways in action to allow survival. Figure 21A shows the mean 
total relative MYOVI fluorescence is higher in MCF7 than in HeLa and while this level remains 
relatively constant in MCF7 under extending hypoxic condition, HeLa exhibit fluctuating levels 
of fluorescence with the highest value exhibited at 5 hours hypoxia.  
Figure 21B allows the nuclear fluorescence of both cell lines to be compared. Both show a a 
positive correlation of nuclear MYOVI fluorescence with increasing time under hypoxic 
conditions, however the levels seen in MCF7 are higher than that seen in HeLa. This is 
especially prominent after 5 hours of hypoxia where the nuclear fluorescence of MYOVI is 
double that of HeLa in MCF7.  
Most striking is the change in phenotype of both cell lines upon increasing exposure to hypoxia. 
HeLa morph into filamentous cells and lose adhesion abilities resulting in cells being largely 
spaced apart and mass cell death is seen. MCF7 however exhibit very little cell death and tend to 
clump into masses. Examples of this can be seen in the hoescht stained images in Figure 20 and 
were seen in three separate experiments in 70% of the cells fixed to each slide.   
 
























Figure 21: A- A Bar graph showing MYOVI total cell fluorescence in MCF7 and HeLa in 0, 5 
and 24 hour hypoxic states. Standard deviation was calculated from raw data collected from 3 
single cell microscopy images from different slides for all the conditions. B- A Bar graph 
displaying the variance in nuclear fluorescence of MYOVI in both MCF7 and HeLa during 
increasing time under hypoxia. Three nuclei were examined for each condition. 
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4.0: Summary and Discussion 
4.1: Assessing the effect of the ESR1-DAB2 fusion as an intrinsic stressor in MCF7 and HeLa 
The ESR1-DAB2 fusion has lost ERü and Dab2 antibody binding epitopes 
The primary aim of any transfection is to ensure that the expression of the resultant intrinsic 
protein can be detected. Typically, this is through a GFP tag introduced to the plasmid which 
allows instant recognition of a successful transfection using microscopy as cells fluoresce green 
if they express the introduced protein. In the case of ESR1-DAB2 detection has not been as 
simple.  
The nature of the resultant fusion led to the secondary antibody signal being too weak to 
differentiate transfected cells from those expressing background fluorescence when imaged with 
the confocal. This indicated that the primary DAB2 and ERg antibodies were unable to 
successfully bind to the fusion protein. This could be due to deletion of the recognized epitope 
by the introduction of DAB2 in the middle of ESR1, or as a result of internalization of the 
complimentary epitopes, therefore sterically hindering the binding of primary antibodies after 
tertiary folding and protein maturation (Supplementary Material Fig.1). The plasmid does in fact 
have an-RFP type fluorophore attached to allow direct detection within cells; however this tag 
(Rudolph RFP) possesses an odd emission spectra and fluorescence properties that were not 
viable to image using the microscopes available(Supplementary material- Fig.2). The final 
option therefore was to utilize the HA tag and acquire a primary antibody that would allow this 
to be imaged. Ideally this would only detect the ESR1-DAB2 fusion, but as seen in section 3.1, 
both control samples in HeLa and MCF7 express some level of background non-specific binding 
of this HA antibody. Nevertheless, this allows the control fluorescence to be compared to that 
seen in the ESR1-DAB2 transfected samples to confirm a successful transfection.  
Transfections were performed using two methods which involved very different delivery of the 
plasmid into the nucleus of the cell. In previous work re-introducing DAB2 into MCF7, 
lipofectamine was often too toxic and transfections were unsuccessful where positive results 
were only obtained from electroporation transfections. In regards to MYOVI expression and 
localization, the two methods of transfection allowed for a comparison and quantification of 
nuclear and cytoplasmic populations of the protein in both control and transfected samples.  
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Both methods of transfection were successful in introducing the ESR1-DAB2 plasmid in both 
cell lines as seen in the increase in the mean total cell fluorescence of HA increasing throughout. 
However, as expected lipofectamine induces a wider range of fluorescence in both cell lines 



















Figure 22: Breakdown Diagram of ESR1-DAB2 fusion plasmid produced by the University of 
Pittsburg Cancer institute.  
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In respect to the function of ESR1-DAB2 within the cancer field, it is integral to examine the 
function of this fusion within cells and the variation in function depending on the localization of 
this protein. This novel gene’s function has not been explored post-isolation from a metastatic 
breast cancer patient resistant to therapy. Therefore in vitro studies of its effect on cellular 
functions within a cervical cancer cell line and breast cancer cell line are invaluable in collecting 
evidence to suggest signaling pathways that it acts on resulting in this aggressive cancerous 
phenotype. From a clinical perspective, this could allow for the production and trial of 
combinatory treatment or a new drug altogether to treat these patients who have no current 
options.  HeLa do not express the ESR1 hormone receptor endogenously, allowing the 
introduction of ER to be evaluated in respect to its action in altering the protein population and 
expressed gene profile of these cells and compared to the hormone receptor positive MCF7 cell 
line. 
ESR1-DAB2 localizes within the nucleus in HeLa 
Within the cytoplasm PKA, PAK1, Akt and MAPK can ct on ERg allowing its 
phosphorylation(41). This is integral for hormone independent activation within HeLa, as they 
do not posses hormone receptors like MCF7, instead RTK’s on the plasma membrane bind to 
growth factors and result in the activation of these cytoplasmic kinases which are able to 
phosphorylate ERg. Hence in both lipofectamine and electroporation transfections, where the 
HA fluorescence within the nucleus is seen to double, suggest that the ESR1-Dab2 fusion protein 
is localized within the nuclear compartment. In this case non-phosphorylated ERg can bind to 
SP-1 and AP-1 resulting in an alternative hormone independent pathway of transcribing target 
genes; SP-1 targets CG-rich areas within promoter sequences of genes that control cell 
proliferation and metastasis(42,43) and AP-1 regulates VEGF induced endothelial proliferation 
(44). Furthermore AP-1 functions to enhance cell invasion via targeting of zinc finger E-box 
binding homeobox 2 (ZEB2) which downregulates E-cadherin(45).ERg phosphorylated in the 
cytoplasm further influences transcription of downstream target genes by binding to ERE’s in 
this activated form post migration to the nucleus (46). 
 However, the fusion protein also contains Dab2, which is endogenously expressed in HeLa and 
functions as a tumour suppressor. Considering that the expression of ESR1-Dab2 will result in an 
increase in the levels of functional Dab2 within these cells, there will consequently be an 
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increase in suppression of Wnt signaling, ERK and TGF-く, pathways associated with metastasis 
and aggressive cancer phenotypes(47, 48, 49) .  DAB2 functionality is exclusively confined to 
the cytoplasm where it can act on proteins involved in these signaling pathways. ERK1/2 
functions within the cytoplasm of cells to activate AP-1 and cyclin-D within the nucleus which 
lead to cell cycle progression, cell survival, proliferation and angiogenesis (50).Wnt upregulates 
the activation of く-catenin which accumulates within the cytoplasm before entering the nucleus 
and exerting its ability in upregulating cell proliferation(51). The images obtained of HeLa 
through microscopy shows that in both lipofectamine and electroporation transfections, HA 
fluorescence is mainly exhibited in the cytoplasm, hence the majority of interactions of the 
ESR1-Dab2 protein will occur here. I would like to highlight that there is crosstalk between the 
ERg pathway and Dab2 pathway involving the activation of AP-1. While endogenous Dab2 and 
cytoplasmic ESR1-Dab2 functions to downregulate nuclear AP-1 activation by suppressing the 
action of ERK1/2, non-phosphorylated ERg within the nucleus can independently activate AP-1. 
The nuclear proportion of the ESR1-DAB2 protein, which is seen to be present and doubles from 
the control to the transfected samples, may be interacting directly with DNA via ERE’s and 
transcription factors, to alter the expression of proteins within HeLa as Dab2 does not exhibit 
nuclear function.  
Introduction of ESR1-Dab2 alters MYOVI distribution and exhibit co-localization 
As the introduction of ESR1-DAB2 seems to exhibit tumour suppressive, through the action of 
DAB2, and enhancing properties it is difficult to determine whether this causes a more malignant 
phenotype within HeLa. Therefore as increased MYOVI is associated with more aggressive 
cancer phenotypes(52,53), we can look to its expression and localization in order to reveal more 
about the effect of this fusion within HeLa.  
The mean total cell MYOVI fluorescence remains stable between control and transfected cells 
using both electroporation and lipofectamine transfection methods. The lack of an increase in 
fluorescence indicates that introduction of ESR1-DAB2 does not affect the expression of MYOVI 
within cells. In lipofectamine transfections however the level of nuclear MYOVI decreases upon 
transfection with ESR1-DAB2 suggesting that a population of MYOVI exits the nucleus and 
performs cytoplasmic functions. As a large proportion of the ESR1-DAB2 protein is also located 
here this suggests that LI MYOVI may be interacting with the fusion via the WWY motif as well 
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as with endogenous DAB2 (54). The interaction of MYOVI LI with DAB2 results in its specific 
targetting to lipid membranes where it functions as a homodimeric endocytic motor and clusters 
transmembrane receptors close to clathrin-coated pits (55). From images acquired through 
microscopy the HA signal does seem to co-localize more strongly in transfected samples 
(especially in electroporation) in comparison to the controls. This suggests that the function of 
DAB2 is predominant over the function of ER within the nucleus on gene expression in 
repressing the activation of ERK1/2 and the Wnt signaling pathway. Moreover we would expect 
to see an increase in total MYOVI due to its downstream upregulation by ERg if the ESR1-
DAB2 protein was heavily involved in affecting gene transcription within the nucleus (56).  
ESR1-Dab2 localizes to nuclear compartment in MCF7 
Contrastingly MCF7 have lost the endogenous expression of DAB2 but retain expression and 
function of ERg and are therefore a hormone sensitive cell line. In lipofectamine transfections 
the nuclear fluorescence of HA is seen to increase dramatically suggesting that there is a large 
population of the fusion protein active within the nucleus. As DAB2’s function is limited to the 
cytoplasm, this enrichment within the nucleus proposes that the ESR1 segment of the fusion is 
resulting in this localization and hence we must consider its function within the nuclear 
compartment.  
A proportion of endogenous ERg (23%) is able to form homodimers via HBD and DBD 
domains, stabilized by E2, within the cytoplasm which then enters the nuclear compartment (57), 
however in the case of the fusion protein; we have collected no evidence to indicate that this is 
possible or occurring. MCF7 also express HER2 and EGFR on the plasma membrane(58). 
Activation of the ER signaling pathway can originate at these RTK’s which contain one 
transmembrane ü-helical structure. Dimerisation is induced by the binding of a signaling 
molecule, which results in phosphorylation of the cytosolic proportion of these receptors; ERg 
binds to the cytosolic segment, following lipidation by caveolin-1, which enables E2 activated 
ERg to associate with Src, PI3K and G-coupled protein gi . The resultant activation of RAS, a 
small protein bound to the plasma membrane via a lipid tail, by GTP causes downstream 
signaling by activating the MAP-kinase cascade. This acts on PI3K within the cytoplasm, 
producing active MAPK and mTOR, which phosphorylate ERg within the nucleus (59, 60). 
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Once achieving nuclear localization ERg can act upon ERE’s driving the expression of cyclin D1 
and CDK4/6, resulting in passage past the G1 checkpoint (61).  
ERg has been found to maintain multiple estrogen (E2) dependent interactions within the 
nucleus, requiring the prior phosphorylation of ERg. One such interaction with cytoplasmic gene 
regulatory protein STAT, after phosphorylation by PI3K and resultant migration to the nucleus, 
can directly bind to active chromatin and up-regulate the expression of genes associated with 
proliferation and survival (62).  AP-1 can also be activated via this hormone dependent pathway 
where ERg in addition to Fos and Jun form a complex to bind DNA. These interactions result in 
targeting upregulation of genes involved in cell survival, proliferation and metastasis while 
down-regulating expression of caretaker genes. Such qualities are associated with more 
aggressive cancer phenotypes and hence indicate that the introduction of ESR1-DAB2 and its 
presence within the nucleus may be enhancing the endogenous ERg signaling capabilities. While 
this may be the case, we would also expect to see a dramatic increase in nuclear MYOVI, which 
from the microscopy images is not found to be present.  
Conversely in electroporated samples the nuclear level of HA and hence the level of the fusion 
protein is not altered from the control, indicating that the dramatic increase in total cell HA 
fluorescence and successful transfection of ESR1-DAB2 is due to a cytoplasmic population of 
this protein. The total cell MYOVI level is also seen to double but this is not reflected in a 
doubling of the nuclear fluorescence. Indicating that MYOVI is also enriched within the 
cytoplasm and hence not co-localizing with RNAPII  in transcription factories at active genes.  
ESR1-DAB2 has a function within the cytoplasm of MCF7 
As the distribution of ESR1-DAB2 in the electroporated sample is mirrored in MCF7 to that in 
HeLa, the cytoplasmic role must be considered, specifically in order to suggest why there is 
disparity between the localization and hence function depending on the method of transfection. 
One possible scenario, bearing in mind that MCF7 already expresses ERg endogenously, is that 
the protein is confined to the cytoplasm awaiting phosphorylation and activation by E2. Taking 
into consideration the doubled level of total MYOVI and its enriched presence within the 
cytoplasm, this could indicate that the Dab2 portion of the fusion is interacting with MYOVI. I 
will once again mention that there is no endogenous DAB2 expression in this cell line. This is 
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specifically important here as DAB2 interacts within the ER ligand dependent signaling pathway 
by acting as a negative regulator of ERK1/2 signaling (63).  ERK1/2 is activated downstream of 
ERg binding to E2 via MEK1/2 and induces transcriptional changes via cyclin-D and AP-1 
within the nucleus. Over activation of this pathway due to an increase in ERg within this 
hormone responsive cell line could result in Dab2 recruitment to ERK1/2, preventing 
phosphorylation to its active form due to its saturation within the cytoplasm(64). This would 
explain the increased cytoplasmic HA fluorescence and the lack of increased nuclear MYOVI. 
The western also does not show a definitive increase in MYOVI between the samples loaded, 
suggesting that ERg within the nucleus is not targeting upregulation of MYOVI transcription.  
Alternatively the lack of increase in MYOVI could be attributed to ERg’s direct feedback loop 
with P53 (65). P53 binds directly and activaed MYOVI’s promoter region, its nuclear function 
is repressed by ERg and this could explain the homeostasis maintained in respect to MYOVI 
expression (66). 
Electroporation with ESR1-DAB2 results in nuclear MYOVI structure 
The microscopy images revealed another interesting aspect of MYOVI expression within both 
HeLa and MCF7 electroporated samples. It is clear to see that in both instances MYOVI within 
the nucleus seems to localize along a linear structure through the centre of the nucleus. Hoechst 
staining reveals that the cell is not dividing and therefore this pattern of localization is intriguing. 
There seems to be no co-localization with the HA fluorescence signal in these cases perhaps 
suggesting that this is an indirect effect or that electroporation results in the formation of F-actin 









4.2: Assessing the effect of hypoxia as an extrinsic stressor on MCF7 and HeLa 
Due to differences in expressed genes within HeLa and MCF7, it is particularly interesting to 
observe the differing effects of hypoxia on these cell lines and compare how MYOVI expression 
and localization is effected as a result of this extrinsic stressor. Hypoxic conditions mimic the 
tumour microenvironment and hence changes in cell phenotype and protein expression can infer 
how and why cells in a tumour mass are able to survive without an immediate oxygen source. 
Hypoxia can induce a metastatic phenotype as well as increasing glycolysis within cancer cells 
however intermittent hypoxia has been suggested to have therapeutic potential (68). From a 
clinical perspective, studying this pathway can allow for more aggressive tumour masses to be 
treated, and can offer some suggestion as to why current therapies used are unsuccessful in 
hypoxic tumours (69).  
MYOVI is enriched in HeLa nuclei after 5 hours exposure to hypoxia 
These experiments focused on only the changes in endogenous expression of MYOVI and Dab2 
or ERg in HeLa and MCF7 respectively. Microscopy of HeLa indicated that this cell line could 
only endure smaller exposure to hypoxia, with the majority of cells at 24 hours dying or 
expressing high stress states. Therefore we will mostly compare the differences between the 
control sample (0 hours) to the 5 hour hypoxic sample. While there is a large range of variation 
in fluorescence the mean total fluorescence of MYOVI is seen to double after 5 hours. This is 
paired with an increase in MYOVI nuclear fluorescence indicating that specifically the NI 
MYOVI isoform is enriched in the nucleus as a result of hypoxia. The location of a protein is 
synonymously indicative of the function it is performing; hence this increase in MYOVI within 
the nucleus suggests that it is interacting in complex with RNAPII which occurs during 
transcriptional activity (70). This makes sense under hypoxia because the cell will be responding 
the external stressor and altering its transcriptional activity in order to upregulate the 
transcription of genes allowing survival. In normoxia HIF-1g is rapidly degraded by the 
proteasome complex following polyubiquitination and interaction with Von Hippel-Lindau 
(VHL), a tumour suppressor. This process is regulated by oxygen-dependent prolyl hydroxylase 
domain (PHD) enzymes which ensure the rapid degradation of HIF-1g (71).  
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Hypoxia sensing within cells occurs when HIF-1く and HIF-1g combine to form HIF-1 which can 
translocate and bind to DNA in the nucleus inducing up-regulated expression of genes involved 
in metabolic adaptation, apoptosis resistance, angiogenesis and metastasis (72). It is clear that 
this change in expression pattern within HeLa results in a more aggressive phenotype that has 
been seen to exhibit resistance to treatment such as radiotherapy. HIF-1 functions as a 
transcription factor allowing cells to survive hypoxic conditions by up-regulating the expression 
of glycolytic genes. HIF-2g is also suggested to be responsible for the metabolic adaptation seen, 
hence promoting cell viability (73).  
The mean total fluorescence of DAB2 was also seen to increase and from the microscopy images 
it is predominantly localized in the cytoplasm where it can interact with MYOVI. This 
interaction allows MYOVI’s targeting to lipid membranes and resultant activation to function as 
an endocytic motor via dimerisation (74). Hypoxia has been seen to induce internalization of 
receptors and hence this could explain the enrichment of MYOVI in the cytoplasm performing 
this function (75, 76). Furthermore, increased MYOVI expression results in enhanced secretion of 
VEGF, where transcription is up-regulated as a downstream target of transcription factor HIF-
1(77).  
High toxicity in HeLa exposed to 24 hour hypoxia 
In regards to the toxicity seen at 24 hours hypoxia, which is not seen in MCF7, the main 
expression difference is the lack of ERg in HeLa (78). The expression of HIF-1g is directly 
controlled by ERg with the HIF-1 gene containing an ERE, which ERg can bind, hereby up-
regulating transcription (79). As HeLa cannot activate this signaling pathway, the levels of HIF-
1g will be lower than that in MCF7, hence resulting in the cell death observed as downstream 
survival targets are not activated in large enough quantities to cope with the hypoxia (80).   
24 hour hypoxia results in upregulation of MTA1 ERü repression in MCF7 
Within MCF7 the total mean fluorescence of ER was observed to decrease after 24 hours of 
hypoxia where previously in the control and 5 hour samples the level remained stable.  The 
sustained hypoxia results in the upregulation of MTA1 (81). MTA1 forms a complex with a 
histone deacetylase (HDAC) (NuRD complex), which not only stabilizes HIF-1g but also 
represses ERg transactivation within the nucleus(82).It’s function extends to the cytoplasm also 
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where MTA1 binds ERg, preventing its entry into the nucleus to bind to ERE’s (83). This 
explains the decrease in nuclear fluorescence seen in the microscopy images as transcription of 
ERg is being repressed and any cytosolic ERg internalized upon E2 binding will be immobilized 
by MTA1.  
MYOI is enriched in the nucleus of MCF7 after 5 hour exposure to hypoxia 
While the total mean level of MYOVI fluorescence remains stable in MCF7, the nuclear 
expression is seen to double at 5 hours from the control and then plateau out at 24 hours. This 
suggests that MYOVI is being recruited to the nucleus in order to enhance RNAPII transcription 
of the genes up-regulated by hypoxia which ultimately results in cell survival and continued 
growth (84). Furthermore MYOVI localization within the cytoplasm seems to favor apical 
membranes at 24 hours hypoxia. Levels of autophagy are seen to be increased in cells exposed to 
this extracellular stressor(85), hence MYOVI may be functioning in facilitating autophagosome 
formation via interactions with nuclear dot protein 52 (NDP52) and Traf6 binding protein 
(T6BP), resulting in its prominent localization at this membrane(86, 87). Furthermore MYOVI is 
able to form complexes with adhesion proteins E-cadherin and く-catenin which span the plasma 
membrane and therefore it may be localizing here in support of the literature suggesting MYOVI 
and hypoxia increase cell motility and metastasis (88). Interestingly the phenotype of MCF7 cells 
seems to change to favor clustering; this is possibly in order to share a pool of growth factors that 
these cells are excreting, specifically VEGF that as mentioned has increased secretion under the 
action of MYOVI.  
4.3 Conclusions 
From the data presented, I am confident in saying that transfection of ESR1-DAB2 was 
successful in both MCF7 and HeLa, where electroporation seemed to be more effective in 
producing a smaller variance in results either side of the mean fluorescence measured. Using 
microscopy images to collect quantative data has its limitations as fluorescence ranges between 
cell lines making direct comparison difficult as well as within an individual cell line. However, 
without obtaining a HA-positive control sample a western blot could not be performed and the 
westerns performed alongside confocal microscopy lead us to believe that neither the DAB2 not 
ERg antibodies were able to detect the fusion.  
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Intrinsic stress in the HeLa cells and resulted in lower nuclear MYOVI levels in comparison to 
that elicited by the extrinsic stressor hypoxia. The literature suggests this may be due to NI 
MYOVI interacting with RNAPII to enhance its transcription activity of preferentially up-
regulated genes enabling cell survival and associated with metastasis. In MCF7 specifically 
MYOVI is seen to clump within the nucleus suggesting that they may be performing a function 
within a transcription factory where a set of related genes are actively transcribed.  
The total level of MYOVI in HeLa induced by the external stressor increases with extended 
exposure which contrasts to the expression pattern exhibited by ESR1-DAB2 transfection where 
it is observed to remain at a steady level. Contrastingly MCF7 exhibits the opposite pattern with 
the extrinsic stressor eliciting no change in total MYOVI but the internal stressor (introduction of 
ESR1-Dab2) causes an increase in total MYOVI.  
Under the action of an extrinsic stressor MYOVI within MCF7 is seen to localize at apical 
membranes and this is similar to the distribution pattern seen in lipofectamine transfections 
suggesting that its main function in these states is confined to interactions with membrane 
proteins and endosomes within the cytoplasm. However, in electroporation transfections MYOVI 
can be seen to strongly localize along the external nuclear membrane and co-localizes with the 
ESR1-DAB2 protein, which is not seen in hypoxia with endogenous ERg. This co-localization 
seems to be more limited in lipofectamine transfections and in HeLa. MYOVI and endogenous 
DAB2 within HeLa under hypoxia show higher co-localization than that seen to be induced by 
ESR1-DAB2. 
At 5 hours hypoxia MCF7 exhibits significantly higher nuclear MYOVI levels than that seen in 
HeLa and while the total MYOVI fluorescence is seen to be steady in response to this extrinsic 
stressor, HeLa’s MYOVI levels fluctuate greatly. In both cell lines 5 hours under hypoxia seems 
to induce a wider range of effects seen in the wide range of fluorescence exhibited suggesting 
that this is where the majority of expressional protein changes are occurring in response to the 
extrinsic stressor. In HeLa the cells do not respond fast enough and therefore they exhibit higher 
apoptosis than that observed in MCF7 who are very efficient in activating downstream signaling 





4.4 Future directions and improvements 
While many of the initial aims have been fulfilled by the research collected and displayed here it 
seems that this is simply the tip of the iceberg. The lack of research involving ESR1-Dab2 within 
the cancer field means that this research has opened up a whole network of questions and hence 
future directions for additional research. Furthermore, as is common with cell work, there seems 
to be a large plethora of improvements that can be made in order to create a stronger portfolio of 
data supporting one hypothesis. In order to achieve successful transfection of ESR1-Dab2 within 
these cell lines there was a very large and long optimization procedure, as is expected when 
performing novel work with novel constructs, which significantly impacted the time frame 
available to obtain results. 
In terms of confirming transfection and determining the amount of resultant protein in the 
cytoplasmic and nuclear fractions of HeLa and MCF7, it would be ideal to be able to perform a 
western blot, probing for the HA tag. In order to assess the nuclear localization of ESR1-DAB2, 
nuclear isolation and lysis could be performed, allowing the amount of fusion protein within this 
cellular fraction to be assessed and compared to the total cell protein levels. Additionally, it 
would be interesting to assess the fusions function in comparison to endogenous ERg or DAB2 
in MCF7 and HeLa respectively. Knockdowns of these endogenous proteins could be performed 
using miRNA or siRNA, ensuring a reduced level of the expressed protein before transfecting 
them with ESR1-DAB2.  
To evaluate the proposed interaction between ESR1-DAB2 and MYOVI, immunoprecipitation 
using a MYOVI antibody attached to the beads in the column would allow for a pull down of 
proteins forming interactions with this unconventional motor protein. The collected proteins can 
then be run on a gel in order to determine their size and hence identify them. Should ESR1-
DAB2 appear, it would be beneficial to quantify this interaction through a protein binding assay, 
allowing comparison to endogenous DAB2 binding strength.  
Expressing and purifying the ESR1-DAB2 protein would allow the structure to be studied by 
crystallography to observe expression of functional domains and ensure correct folding. This 
information is transferrable not only to create mutants but also to design a more specific antibody 
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for IF and western blots, reducing the background fluorescence seen by using HA antibody. 
Recombinant DNA technology would allow the construction of mutants, the change in 
localization of these mutants can allow for the functional domains involved in nuclear 
localization, DNA binding and MYOVI binding to be highlighted.  
The nuclear MYOVI structure seen in electroporation samples could also be probed with actin 
antibodies to determine if this structure is formed by association with this cytoskeletal 
component.  
Hypoxia has been widely studied as it is seen in physiological processes (embryonic 
development) and a number of pathophysiological conditions such as atherosclerosis, mountain 
sickness and of course cancer (89). Within the cancer field, the literature documenting it’s effects 
is extensive, and reveals that hypoxia can result in more aggressive phenotypes or be used as a 
treatment for specific tumours. This means that many future directions from this research are 
already being studied, nevertheless the complexity of the system and variation between 
individual cancers means that the opportunity to accrue more knowledge is endless.  
In order to see if the apoptic phenotype observed within HeLa exposed to 24 hours hypoxia is 
due to the lack of ERg signaling and hence reduced upregulation of HIF-1g, a knockdown of 
endogenous ERg in MCF7 could be performed before exposure to hypoxia. The comparison of 
the resultant phenotypes could elucidate how strongly the presence of ERü interacts with 
signaling pathways activated in hypoxia and if it’s deficiency in cells causes apoptosis under this 
external stressor.  
Intermittent hypoxia is suggested to be a method of therapy for treating cancerous tumours, 
therefore it would be interesting to observe the effects of this cycling hypoxia and normoxia on 
MYOVI levels and distribution to determine if protein expression is returned to that observed in 
the control or if the expression remains altered.  
As resistance to current cancer therapies is observed in patients with ESR1 mutations and 
hypoxic tumour microenvironments, examining the change in MYOVI alongside gene 
expression in these experiments when cells are also treated with a drug currently in clinical use 
(such as tamoxifen) may allow the methods of resistance to be observed. Potential drugs that can 
[63] 
 
be used in combinatory treatment to preserve the efficacy of treatment can then be highlighted 
and tested in the same way.  
The final suggestion for future research is to combine the introduction of intrinsic and extrinsic 
stressors. Exposing ESR1-DAB2 expressing cell lines to hypoxia may be more realistic to the 
microenvironment observed in breast cancer patients with ESR1 mutations. Hence, observing the 
resultant phenotype and protein expression could allow for the pathways activated to be 
understood more deeply, allowing us to expose the methods by which they enable metastasis of 
the primary tumour and a more aggressive phenotype via resistance. This could be done by 
creating a stable cell line expressing ESR1-DAB2 and comparing the reaction of these cells in 
hypoxia to HeLa stably expressing ERg and MCF7 stably expressing DAB2. RT-qPCR can be 
used to detect changes in mRNA transcripts, hereby quantifying which genes are being actively 
expressed and up-regulated or down-regulated. Furthermore the relationship between MYOVI 
and genes up-regulated in this condition can be explored using ChIP, revealing if MYOVI alters 
gene transcription by functioning in a complex to recruit RNAPII to DNA.  
Collecting a wider range of data is beneficial to determine exactly what the ESR1-DAB2 protein 
is doing within a cell and to see if hypoxia could act as a potential treatment for breast cancer 
patients exhibiting this ESR1 mutation who have been seen to be resistant to other routes of 
therapy. Elucidating the signaling pathways involved in these altered stress states will provide 
invaluable information for progress within the cancer field and may have limitless clinical 
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Figure 3: RudolphRFP fluorophore excitation and emission spectra. The 
fluorophore is created and supplied by ATUM. 
Figure 1: A screenshot of ESR1-Dab2 plasmid sequence screened using basic local alignment search 
tool (BLAST) created by Uniprot.org. 
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Primers  Conditions (1/10 cDNA dilution)  
B-actin  (1) HeLa control 
(2) HeLa ESR1-Dab2 fusion 
(3) MCF7 Control 







Figure 2: A: A table to display Primers used in PCR techniques and corresponding samples 
used. Transfection technique used was lipofectamine where RNA was extracted from these 
cell samples B: Gel of resultant qPCR cDNA products where primer-dimer is the only band 







Figure 1: Full images of western blots performed on MCF7 hypoxia samples displaying 
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